Rallis India delivers resilient kharif season performance in Q2 FY27 amidst challenging operating environment; H1 FY27 Revenue & PAT grew 3% and 6% respectively.

Rallis/PR/03/2627/Corp 

Rallis India delivers resilient kharif season performance in Q2 FY27 amidst challenging operating environment; H1 FY27 Revenue & PAT grew 3% and 6% respectively.

Mumbai, October 22, 2026: Rallis India Limited (A TATA Enterprise), a leading player in the Indian agri inputs industry, announced its financial results for the second quarter and half year ended September 30, 2026.

Key Highlights: Q2 & H1 FY27

Announcing the results, Dr. Gyanendra Shukla, Managing Director & CEO, Rallis India Limited, said: Rallis navigated a disruptive business environment during Q2 FY27 by focussing on portfolio and operational efficiencies. 

During the quarter, the Company recorded revenue of ₹858 crore, compared to ₹861 crore in Q2 FY26. PAT stood at ₹85 crore, compared to ₹102 crore in the corresponding quarter last year, while EBITDA stood at ₹126 crore, against ₹154 crore in Q2 FY26. The Company’s EBITDA margin stood at 14.7%, while PAT margin was 9.9%. For the half year ended September 2026, Rallis reported revenue of ₹1,880 crore, compared to ₹1,818 crore in H1 FY26. EBITDA stood at ₹311 crore, against ₹304 crore in the previous year, while PAT stood at ₹210 crore, compared to ₹197 crore in H1 FY26. The Company’s EBITDA margin was 16.5%, while PAT margin stood at 11.2%. 

Business Performance: Q2 FY27 

The Crop Care business recorded topline growth of 4%, primarily driven by 17% growth in the B2B segment with a strong recovery in CSM portfolio. Domestic Formulations (B2C) remained flat year-on year, supported by 16% growth in herbicides, while insecticides registered flat growth. The Soil & Plant Health (SPH) business recorded 22% growth, primarily driven by price growth.

During the quarter, in the Crop Care category, Rallis launched four new products—Silentra (Insecticide), Marcellus (Fungicide), Blitox Super (Fungicide) and Trynage (Herbicide). The new products cater to critical crop-pest segments like Rice BPH and sheath blight segments, sugarcane herbicide and disease control in key horticulture crop.
The Seeds business recorded a decline, primarily due to higher returns from the Kharif season. 

Management Comment 

Weather-related disruptions and delayed sowing continued to impact market demand during the quarter/season. We remain focused on improving market execution, driving cost efficiencies and strengthening customer engagement to navigate these challenges and enhance business performance. 

About Rallis India: Rallis India Limited is a subsidiary of Tata Chemicals Limited and a part of over US$ 180 billion Tata Group. Rallis is one of India’s leading agri science companies, with more than 77 years of experience in serving rural markets with a comprehensive portfolio of products/solutions for Indian farmers. Rallis is known for its deep understanding of Indian agriculture, sustained connect with farmers, quality agrochemicals, branding and marketing expertise along with its strong product portfolio in seeds and crop care which is available through a vast distribution network of 7,200 dealers and over 95,000 retailers across India. Rallis has marketing alliances with several multinational agrochemical companies. Rallis is also known for its manufacturing capabilities and ability to develop new processes and formulations; hence it is considered a preferred partner for contract manufacturing by leading global corporations. 

Explore other press releases

  • Tata Chemicals Mithapur Launches ‘Suraksha Gurukul’ Safety Training Centre

  • Tata Chemicals Mithapur Wins Two Platinum Awards at 21st CII National Six Sigma Competition

  • Tata Chemicals Wins India Gold MIKE Award 2026 for Excellence in Innovation and Knowledge Management

  • CSIR-CSMCRI study finds Mithapur coastal ecosystem healthy and biodiverse following treated wastewater pipeline transition

  • Tata Chemicals North America acquires customer contracts expected to generate over USD 110 million in revenue through 2028